Clinical trials: ALS (Amyotrophic Lateral Sclerosis)
Amyotrophic Lateral Sclerosis, Brainstem Stroke
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit
This project adds to non-invasive BCIs for communication for adults with severe speech and physical impairments due to neurodegenerative diseases.
- Conditions
- Amyotrophic Lateral Sclerosis, Brainstem Stroke, Muscular Dystrophies, Parkinson's Disease and Parkinsonism
- Trial name
- BCI-FIT (NCT04468919)
- Testing
- BCI-FIT multi-modal access, BCI-FIT adaptive signal modeling, BCI-FIT active querying
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Amyotrophic Lateral Sclerosis, Bulbar Disease
Molecular Imaging Modality by Positron Emission Tomography Using 18F-X : Study of Microglial Activation in Amyotrophic Lateral Sclerosis
PET imaging of activated microglia offers a tool of investigation of a range of brain diseases where neuroinflammation is a component. Amyotrophic lateral sclerosis is the most frequent motoneuronal disease in adult.
- Conditions
- Amyotrophic Lateral Sclerosis, Bulbar Disease, Spinal Disease
- Trial name
- NCT00563537
- Testing
- 18F-X PET SCAN
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis
Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)
The purpose of this pilot study is to characterize changes in postural orientation and equilibrium in early diagnosed ALS patient.
- Trial name
- NCT00956501
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
ALS, FTD
Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach
The goal of this study is to learn from discordant twins affected by Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia the contribution of genetic background versus environmental exposure.
- Trial name
- GENIALITY (NCT06595212)
- Testing
- multiomic profile to assess genetic and environmental risk factiors
- Where
- 3 sites in Italy
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Amyotrophic Lateral Sclerosis
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.
- Trial name
- NCT01511029
- Testing
- Dexpramipexole, Moxifloxacin
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Virtual Peer-to-peer Support Programme for Carers of MND
Background/scope There is growing recognition that family caregiving is a serious public health issue requiring supportive interventions.
- Trial name
- NCT04695210
- Testing
- Virtual peer-to-peer support
- Where
- 25 sites in United Kingdom
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- King's College London
Amyotrophic Lateral Sclerosis (ALS)
Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a rare disease with a worldwide incidence of 2-3 cases per 100,000 individuals/year and it is characterized by progressive neurodegeneration of motor neurons.
- Trial name
- NCT03088839
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
Despite significant progress in the identification of mechanisms involved in motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and other motor system diseases, the actual pathogenesis and cause of these diseases…
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00716131
- Where
- United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis
Exogenous Toxicants and Genetic Susceptibility in ALS
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disease that poses a significant burden for affected individuals and their family members.
- Trial name
- NCT00011154
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amyotrophic Lateral Sclerosis
Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)
The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.
- Trial name
- NCT00846560
- Where
- Israel
- Volunteers
- healthy volunteers welcome
- Sponsor
- Rambam Health Care Campus
Amyotrophic Lateral Sclerosis
Italian Validation of the Beaumont Behavioural Inventory (BBI)
Up to 50% of patients affected with amyotrophic lateral sclerosis (ALS) can show behavioral dysfunctions within the spectrum of frontotemporal degenerations (FTD) - namely, apathy, disinhibition, loss of sympathy/empathy…
- Trial name
- BBI (NCT04440644)
- Testing
- BBI
- Where
- Italy
- Volunteers
- 190 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS)
Discovery and Validation of Protein Structural Complexes in Circulating Biofluids As Novel Biomarkers for Early Diagnosis, Prognosis and Therapeutic Management of Patients Affected by Neurodegenerative Disorders
Neurodegenerative disorders (NDDs), such as Parkinson¿s disease (PD), Alzheimer¿s disease (AD), Frontotemporal dementia (FTD) and Amyotrophic Lateral Sclerosis (ALS) are characterized by aggregation and intracellular accumulation…
- Conditions
- Parkinson Disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Alzheimer's Disease (AD)
- Trial name
- NCT06803784
- Testing
- Genetic: whole genome sequencing, whole exome sequencing
- Where
- Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Amyotrophic Lateral Sclerosis
Study of Structural and Functional Brain Connectivity Changes in ALS (CoALS-II)
This study will try to understand the difference in brain structure between ALS patients and healthy people of similar age. ALS is a condition affecting the nervous system with disruption of the brain networks.
- Trial name
- CoALS-II (NCT05404867)
- Testing
- fMRI
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Dartmouth-Hitchcock Medical Center
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which cases the death of neurons controlling the voluntary muscles.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Cortical Excitability
- Trial name
- NCT03664206
- Testing
- MRS, conventional TMS and treshold tracking TMS
- Where
- Denmark
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sándor Beniczky
Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants
This is a Phase 1, single-center study conducted in 2 parts: Part 1a, single ascending dose (SAD-TDU16519): Double-blind, randomized, placebo-controlled sequential ascending single oral doses including up to 6 cohorts.
- Trial name
- NCT05795907
- Testing
- SAR443820
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Sanofi
Amyotrophic Lateral Sclerosis, ENGRAILED1
Identifying Biomarkers in ALS Patients Using Neuronal Derived Extracellular Vesicles
Rationale. ENGRAILED1 (EN1) is under consideration as a therapeutic approach for amyotrophic lateral sclerosis (ALS). To assess EN1 target engagement in patients, we aim to identify EN1-responsive biomarkers suitable as…
- Trial name
- BALNEV (NCT07334743)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Sporadic Amyotrophic Lateral Sclerosis
Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis
INTRODUCTION: Amyotrophic Lateral Sclerosis (ALS) is a degenerative disease of the motor neurones of the brain and the spinal cord. The pathophysiological mechanisms of the disease remain unknown.
- Trial name
- Fibro-ALS (NCT02969759)
- Testing
- Skin Biopsy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Amyotrophic Lateral Sclerosis
Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology.
- Trial name
- LARMOMIQUE (NCT04953286)
- Testing
- Measure of visual acuity, Interferometry, Samples of basal tears
- Where
- 3 sites in France
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis
Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a rare neurodegenerative disease resulting in loss, primarily, of the motor neurons in the motor cortex, brainstem and spinal cord.
- Trial name
- NCT05974579
- Testing
- 89Zr-DFO-AP-101
- Where
- Canada
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Amyotrophic Lateral Sclerosis, ALS
MRI Biomarkers in ALS
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Motor Neuron Diseases
- Trial name
- NCT02405182
- Testing
- Magnetic Resonance Imaging
- Where
- 6 sites in Canada
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- University of Alberta